• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

    5/23/22 8:00:00 AM ET
    $CFRX
    $CLGN
    $ENLV
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Health Care
    Get the next $CFRX alert in real time by email
    • Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions

       
    • Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals

       
    • Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics

    Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is a pharmaceutical and biotech industry veteran who has led scientific, drug and business development functions throughout his stellar career.

    Dr. Pomerantz has held notable positions in both large pharma and small biotech companies. He served as Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than 150 business development transactions, and as Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals. Following his tenure with large pharma, Dr. Pomerantz joined Flagship Pioneering, which conceives, creates, and develops bioplatform companies. Since its launch in 2000, Flagship has originated more than 100 scientific ventures such as Moderna, collectively resulting in more than $140 billion in aggregate value. On behalf of Flagship, Dr. Pomerantz was appointed President, Chief Executive Officer (CEO), and Chairman of the Board of Seres Therapeutics (NASDAQ:MCRB), a clinical stage biopharma company targeting the human microbiome. While at Seres, he helped close a significant business development transaction with Nestle Health Sciences for a $150 million up-front payment and a total transaction value of approximately $2 billion. Throughout his career, Dr. Pomerantz led the development of 13 drugs that have been approved and launched world-wide in a range of therapeutic areas. He is currently the President, CEO, and Chairman of the Board of Directors of ContraFect Corporation (NASDAQ:CFRX), and serves as a Board member at several other biotech companies including Viracta Therapeutics, Inc. (NASDAQ:VIRX), Indaptus Therapeutics Inc. (NASDAQ:INDP), Collplant Biotechnologies Ltd. (NASDAQ:CLGN), and X-Vax Inc.  Dr. Pomerantz received his B.A. in Biochemistry at Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He received post-graduate training at Massachusetts General Hospital, Harvard Medical School, and Massachusetts Institute of Technology. Dr. Pomerantz is board certified in both internal medicine and infectious diseases. Prior to his career in the biotechnology industry, he was a tenured Professor of Medicine, Biochemistry, and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at Thomas Jefferson University and Medical School.

    "It is an honor to join Enlivex as Vice Chairman of the Board at this important juncture in the Company's evolution," said Dr. Pomerantz. "I have always been interested in the role of macrophages across multiple diseases ever since I was an HIV researcher, and I am fascinated with the preclinical and clinical data demonstrating the broad applicability of Allocetra's novel mechanism of action. These data highlight the potential of this next generation cell therapy to serve patients with a range of diseases characterized by imbalances in macrophage homeostasis. I look forward to collaborating with my fellow Board members and the Company's management team as we work to advance Allocetra's development in sepsis and initiate its clinical program in solid tumors. With talented leadership, strong data, and expected cash runway into Q3 2024, I believe Enlivex is well positioned for sustained success."

    Shai Novik, Executive Chairman of the Board of Enlivex, stated, "Dr. Pomerantz's business development acumen and track record of creating shareholder value by successfully developing drugs make him an ideal fit for Enlivex's Board. We look forward to benefiting from his expert insights as we execute on our clinical and corporate strategy. It is my pleasure to welcome him to the Company as the Vice Chairman."

    ABOUT ALLOCETRA™

    Allocetra™  is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs", as a stand-alone therapy or in combination with leading therapeutic agents.

    ABOUT ENLIVEX

    Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit https://enlivex.com/.

    Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would", "could," "intends," "estimates," "suggests," "has the potential to" and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex's business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex's filings with the Securities and Exchange Commission, including in the Company's most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.

    ENLIVEX CONTACT

    Shachar Shlosberger, CFO

    Enlivex Therapeutics, Ltd.

    [email protected]

    INVESTOR RELATIONS CONTACT

    Eric Ribner

    LifeSci Advisors

    [email protected]



    Primary Logo

    Get the next $CFRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CFRX
    $CLGN
    $ENLV
    $INDP

    CompanyDatePrice TargetRatingAnalyst
    Seres Therapeutics Inc.
    $MCRB
    5/8/2025$6.00Buy → Neutral
    Chardan Capital Markets
    Seres Therapeutics Inc.
    $MCRB
    10/24/2024Neutral → Underweight
    JP Morgan
    Viracta Therapeutics Inc.
    $VIRX
    8/16/2024$5.00 → $3.00Outperform → Market Perform
    Leerink Partners
    Seres Therapeutics Inc.
    $MCRB
    6/26/2023$12.00Outperform
    Oppenheimer
    Seres Therapeutics Inc.
    $MCRB
    4/21/2023$7.00Neutral
    JP Morgan
    CollPlant Biotechnologies Ltd
    $CLGN
    2/17/2023$22.75Buy
    Alliance Global Partners
    ContraFect Corporation
    $CFRX
    7/14/2022$1.00Outperform → Mkt Perform
    SVB Leerink
    ContraFect Corporation
    $CFRX
    7/14/2022$15.00 → $1.00Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $CFRX
    $CLGN
    $ENLV
    $INDP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Rothera Mark bought $49,362 worth of shares (100,000 units at $0.49) (SEC Form 4)

      4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)

      12/4/23 4:54:41 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    $CLGN
    $ENLV
    $INDP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • April 26, 2023 - FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection

      For Immediate Release: April 26, 2023 Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI.  “Today’s approval provides patients and healthcare p

      4/26/23 6:04:21 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    $CLGN
    $ENLV
    $INDP
    SEC Filings

    See more
    • SEC Form 8-K filed by Seres Therapeutics Inc.

      8-K - Seres Therapeutics, Inc. (0001609809) (Filer)

      7/22/25 4:10:29 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indaptus Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)

      7/16/25 4:15:56 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CollPlant Biotechnologies Ltd

      6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      7/14/25 11:28:33 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    $CFRX
    $CLGN
    $ENLV
    $INDP
    Leadership Updates

    Live Leadership Updates

    See more
    • Seres Therapeutics Announces Leadership Transition

      Thomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure additional capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced the appointment of Thomas DesRosier and Marella Thorell as co-Ch

      7/22/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations

      New U.S.-based role to support growth strategy, partnerships, and scaling of rhCollagen product platforms REHOVOT, Israel, July 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced the appointment of Bowman Bagley as Vice President, Commercial North America. In this newly created role, Mr. Bagley will lead the company's commercial strategy and execution in North America, including sales and marketing, logistics, and expansion of market presence for CollPlant's rhCollagen-based products and platform

      7/14/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

      Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

      6/24/25 12:52:00 PM ET
      $AUTL
      $CATX
      $INDP
      $ONCY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations

    $CFRX
    $CLGN
    $ENLV
    $INDP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Indaptus Therapeutics Inc.

      SC 13D/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)

      11/26/24 4:11:08 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Viracta Therapeutics Inc.

      SC 13G/A - Viracta Therapeutics, Inc. (0001061027) (Subject)

      11/14/24 4:33:15 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Enlivex Therapeutics Ltd.

      SC 13G - Enlivex Therapeutics Ltd. (0001596812) (Subject)

      11/14/24 3:29:35 PM ET
      $ENLV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    $CLGN
    $ENLV
    $INDP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Seres Therapeutics downgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets downgraded Seres Therapeutics from Buy to Neutral and set a new price target of $6.00

      5/8/25 8:27:44 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seres Therapeutics downgraded by JP Morgan

      JP Morgan downgraded Seres Therapeutics from Neutral to Underweight

      10/24/24 6:25:19 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viracta Therapeutics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Viracta Therapeutics from Outperform to Market Perform and set a new price target of $3.00 from $5.00 previously

      8/16/24 7:39:54 AM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    $CLGN
    $ENLV
    $INDP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

      CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to discuss second quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 3641971. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours afte

      7/22/25 7:01:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seres Therapeutics Announces Leadership Transition

      Thomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure additional capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced the appointment of Thomas DesRosier and Marella Thorell as co-Ch

      7/22/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations

      New U.S.-based role to support growth strategy, partnerships, and scaling of rhCollagen product platforms REHOVOT, Israel, July 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced the appointment of Bowman Bagley as Vice President, Commercial North America. In this newly created role, Mr. Bagley will lead the company's commercial strategy and execution in North America, including sales and marketing, logistics, and expansion of market presence for CollPlant's rhCollagen-based products and platform

      7/14/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    $CFRX
    $CLGN
    $ENLV
    $INDP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Ausiello Dennis A

      4 - Seres Therapeutics, Inc. (0001609809) (Issuer)

      7/2/25 5:58:32 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Berenson Stephen

      4 - Seres Therapeutics, Inc. (0001609809) (Issuer)

      7/2/25 5:38:55 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Fraser Claire

      4 - Seres Therapeutics, Inc. (0001609809) (Issuer)

      7/2/25 5:34:14 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    $CLGN
    $ENLV
    $INDP
    Financials

    Live finance-specific insights

    See more
    • Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

      CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to discuss second quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 3641971. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours afte

      7/22/25 7:01:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS

      REHOVOT, Israel, May 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter on Wednesday, May 28, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombina

      5/14/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

      In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres' live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions i

      5/7/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care